Validating a FAP-Targeted Glioblastoma Model for Preclinical Imaging and Radioligand Therapy

A reproducible U87MG xenograft platform demonstrating dose-dependent efficacy and tumor retention of [¹⁷⁷Lu]Lu-FAP-2286.

Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, underscoring the need for translational preclinical imaging models that accurately reflect tumor biology. This EORTC 2025 poster presents a validated U87MG glioblastoma xenograft model expressing fibroblast activation protein (FAP), a promising target for radioligand therapy (RLT). Using [¹⁷⁷Lu]Lu-FAP-2286, Perceptive Discovery demonstrates reproducible tumor growth, dose-dependent efficacy, and sustained tumor retention visualized through SPECT imaging up to 72 hours post-dose. These findings establish the model as a reliable preclinical platform for evaluating FAP-targeted imaging agents, radiopharmaceuticals, and other targeted therapies, bridging preclinical insights to early clinical translation.

Why Download the Poster:

• Explore translational RLT development: See how FAP-targeted ¹⁷⁷Lu-based therapy demonstrates selective tumor retention and measurable anti-tumor response.
• Validate preclinical model reliability: Review reproducible tumor growth and biodistribution data supporting model robustness for efficacy and imaging studies.
• Accelerate target-based therapeutic discovery: Learn how this U87MG platform supports translational evaluation of emerging FAP-directed agents across oncology pipelines.